The Use of Low Molecular Weight Heparin in Traumatic Brain Injury
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To study the safety and efficacy of early administration of Low Molecular Weight Heparin to patients with traumatic brain injury.
Condition or disease
Brain InjuryVenous Thrombosis
Venous thromboembolic (VTE) prophylaxis in trauma patients is a critical clinical problem. Patients with traumatic brain injury usually have effective VTE prophylaxis withheld secondary to concerns of exacerbating intracranial hemorrhage. This study examines the safety and efficacy of early administration (within 24 hrs of admission) of low molecular weight heparin to this patient population with very high VTE risk.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Keywords provided by Minneapolis Medical Research Foundation:
Additional relevant MeSH terms:
Wounds and Injuries
Brain Injuries, Traumatic
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System